Genetic and immunologic aspects of cystic fibrosis

Annals of Allergy, Asthma and Immunology

Volumn 79, Issue 5, 1997, Pages 379-394

  Hilman, Bettina C ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS; GENE STRUCTURE; HEREDITY; HUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECURRENT DISEASE; RESPIRATORY TRACT DISEASE; REVIEW;

EID: 0030780774     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63031-1     Document Type: Review

References (119)

1. Dean M, Santis G. Heterogeneity in the severity of cystic fibrosis and the role of CFTR gene mutations. Hum Genet 1994;93:364-8.
2. Tsui LC, Buchwald M, Barker D, et al. Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker, Science 1985;230:1054-7.
3. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-65.
4. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-73.
5. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245: 1073-80.
6. Quinton PM. Chloride impermeability in cystic fibrosis. Nature 1983;301:421-2.
7. Quinten PM. Missing Cl conductance in cystic fibrosis. Am J Physiol 1986;251:C649-C652.
8. Knowles MR, Gatzy J, Boucher RC. Increased bioelectric potential differences across respiratory epithelial in cystic fibrosis. N Engl J Med 1981;305:1489-98.
9. Knowles MR, Stutts MJ, Spock A, et al. Abnormal ion permeation through cystic fibrosis respiratory epithelium. Science 1983;221:1067-70.
10. Welsh MJ, Tsui-L-C, Boat TF, et al. Cystic fibrosis, In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. vol. 3, New York: McGraw-Hill, 1995:799-1876.
11. Jarvi K, Zielenski J, Wilschanski M, et al. Cystic fibrosis transmembrane conductance regulator and obstructive azoospermia. Lancet 1995;345:1578.
12. Boat TF, et al. The diagnosis of cystic fibrosis: consensus statement. Clinical practice guidelines for CF, consensus conferences. Vol. VII, Section I. CF Foundation, Bethesda, MD, 1996.
13. Tsui LC. The cystic fibrosis transmembrane conductance regulator gene. Am J Respir Crit Care Med 1995;151:S47-S53.
14. Frizzell RA. Functions of the cystic fibrosis transmembrane conductance protein. Am J Respir Crit Care Med 1995;151:S54-S58.
15. McIntosh I, Cutting GR. Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J 1992;6:2775-82.
16. Welsh MJ, Anderson MP, Rich DP, et al. Cystic fibrosis transmembrane conductance regulator: a chloride channel with novel regulation. Neuron 1982;8:821-9.
17. Collins FS. Cystic fibrosis: molecular biology and therapeutic implications. Science 1992;256:774-9.
18. Gabriel SE, Clarke LL, Boucher RC, et al. CFTR and outward rec- tifying chloride channels are distinct proteins with a regulatory relationship. Nature 1993;393:263-6.
19. Ma J, Tasch JE, Tao T, et al. Phosphorylation-dependent block of CFTR chloride channel by exogenous R domain protein. J Biol Chem 1995;271:7351-6.
20. Cheng SH, Rich DP, Marshall J, et al. Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channels. Cell 1991;66:1027-6.
21. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
22. Yoshimura K, Nakamura H, Trapnell BC, et al. The cystic fibrosis gene has a "housekeeping"-type promoter and is expressed at low levels in cells of epithelial origin. J Biol Chem 1991;266:9140-4.
23. diSant'Agnese PA, Darling RC, Perera GA, et al. Abnormal electrolyte composition of sweat in cystic fibrosis of the pancreas. Pediatrics 1953;12:549-63.
24. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics 1959;23:545-9.
25. Nussbaum E, Boat TF, Wood RE, et al. Cystic fibrosis with acute hypoelectrolytemia and metabolic alkalosis in infancy. Am J Dis Child 1979;133:965-6.
26. Beckerman RC, Taussig LM. Hypoelectrolytemia and metabolic alkalosis in infants with cystic fibrosis. Pediatrics 1979;63:580-3.
27. Kopelman H, Dune P, Gaskin K, et al. Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med 1985;312:329-34.
28. Kopelman H, Corey M, Gaskin K, et al. Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology 1988;95:349-55.
29. Cotton CU, Davis PB. The pancreas in cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. New York: Marcel Dekker, 1993:161-92.
30. Atlas AB, Orenstein SR, Orenstein DM. Pancreatitis in young children with cystic fibrosis. J Pediatr 1992;120:756-9.
31. Stern RC. CF and the gastrointestinal tract. In: Davis PB, ed: Cystic fibrosis. New York: Marcel Dekker, 1993:401-34.
32. Tomashefski JF, Abramowsky CR, Dahms BB. The pathology of cystic fibrosis. In: Davis PB, ed. Cystic fibrosis. New York: Marcel Dekker, 1993:435-590.
33. + permeability in cystic fibrosis human primary cell culture. J Physiol (London) 1988;405:77-103.
34. + transport in cystic fibrosis respiratory epithelia: abnormal basal rate and response to adenylate cyclase activation. J Clin Invest 1986;78:1245-52.
35. Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847-50.
36. + channel subunits in normal and cystic fibrosis airways. Am J Physiol 1995;269:C511-C518.
37. Goldman MJ, Anderson GM, Stolzenberg ED, et al. Human β-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88:553-60.
38. Cystic Fibrosis Genetic Analysis Consortium. (Consortium Newsletter, May 23, 1996); Website: http://www.genet.sickkids.on.ca/daniel-cgi-bin/news?news=68.
39. Klinger K. Genetic aspects of cystic fibrosis. In: Human BC, ed. Pediatric respiratory disease. Philadelphia: W B Saunders, 1993:652-60.
40. Genzyme Corporation. 70 Mutation cystic fibrosis test. Genzyme Genetics, Framingham, MA, 1997.
41. Shoshani T, Augarten A, Gazit E, et al. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet 1992;50:222-8.
42. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996;4:65-73.
43. Hamosh A, Rosenstein BJ, Cutting GR. CFTR nonsense mutations G542X and W1282X associated with severe reduction of CFTR mRNA in nasal epithelial cells. Hum Mol Genet 1992;1:542-4.
44. Chu CS, Trapnell BC, Murtagh JJ, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. E. M. B. O. J. 1991;10:1355-63.
45. Zielenski J, Tsui LC. Cystic fibrosis: genotypic and phenotypic variations. Ann Rev Genetics 1995;29:777-807.
46. - channels with altered pore properties. Nature 1993;362:160-4.
47. Sheppard DN, Ostedgaard LS, Winter MC, et al. Mechanism of dysfunction of two nucleotide binding domain mutations in cystic fibrosis transmembrane conductance regulator that are associated with pancreatic sufficiency. E. M. B. O. J. 1995;14:876-83.
48. Gaskin K, Gurwitz D, Durie M, et al. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr 1982;100:857-62.
49. Highsmith WE, Burch LH, Zhou Z, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974-80.
50. Augarten A, Kerem B-S, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+10kb C→T mutation. Lancet 1993;342:25-6.
51. Dreyfus DH, Bethel R, Gelfand EW. Cystic fibrosis 3849+10kb C→T mutation associated with severe pulmonary disease and male fertility. Am J Respir Crit Care Med 1996;153:858-60.
52. Anguiano A, Oates RD, Amos JA, et al. Congenital bilateral absence of the vas deferens. A primarily genital form of cystic fibrosis. JAMA 1992;267:1794-7.
53. Chillon MT, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
54. Kiesewetter S, Macek MJ, Davis C, et al. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet 1993;5:274-7.
55. Chu CS, Trapnell BC, Curriston S, et al. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-6.
56. Strong TV, Wilkinson DJ, Mansoura MK, et al. Expression of an abundant alternatively spliced form of cystic fibrosis transmembrane conductance regulator (CFTR) gene is not associated with a cAMP-activated chloride conductance. Hum Mol Genet 1993;2:225-30.
57. Hamosh A, Oates R, Amos J, et al. Correlation of the level of full-length CFTR transcript with pulmonary phenotype in patients carrying R117H and 1342-1, -2 delAG mutation. Pediatr Pulmonol(Suppl)1994;10:124A.
58. National Committee for Clinical Laboratory Standards: Sweat testing: sample collection and quantitative analysis - approved guidelines 1994; [Document C34-A,]: (940 W. Valley Road, Suite 1400, Wayne, PA 19087).
59. Constantinescu M, Hilman BC. The sweat test for quantitation of electrolytes: a challenge in precision. Lab Med 1996;27:472-7.
60. LeGrys VA. Sweat testing for the diagnosis of cystic fibrosis: practical considerations. J Pediatr 1996;129:892-7.
61. 508 cystic fibrosis. Pediatrics 1996;97:524-8.
62. Boucher RC. Human airway ion transport. Am J Respir Crit Care Med 1994;150:271-81, 581-93.
63. Knowles MR, Gatzy J, Boucher RC. Relative ion permeability of normal and cystic fibrosis epithelium. J Clin Invest 1983;71:1410-8.
64. Alton EW, Currie D, Logan-Sinclair R, et al. Nasal potential difference: a clinical diagnostic test for cystic fibrosis. Eur Respir J 1990;3:922-6.
65. McCray PB Jr, Wohlford-Lenane CL, Snyder JM. Localization of cystic fibrosis transmembrane conductance regulator mRNA in human fetal lung tissue by in situ hybridization. J Clin Invest 1992;90:619-25.
66. McGrath SA, Basu A, Zeitlin PL. Cystic fibrosis gene and protein expression during fetal lung development. Am J Respir Cell Mol Biol 1993;8:201-8.
67. Sturgess J, Imrie J. Quantitative evaluation of the development of tracheal submucosal glands in infants with cystic fibrosis and control infants. Am J Pathol 1982;106:303-11.
68. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-82.
69. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. Brit Med J 1995;310:1571-2.
70. Balough K, McCubbin M, Weinberger M, et al. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995;20:63-70.
71. Copenhaver S, Sage A, Vasil A, et al. BALF PCR and ELISA identification of non-culturable Pseudomonas aeruginosa in infants and toddlers with cystic fibrosis. Pediatr Pulmonol (Suppl)1996;13:291A.
72. Konstan MW, Milliard HA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-54.
73. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152:2111-8.
74. Bonfield TL, Konstan MW, Burfeind P, et al. Normal bronchial epithelial cells consistently produce the anti-inflammatory cytokine/interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995;13:257-61.
75. Egan M, Flotte T, Afione S, et al. Defective regulation of outwardly rectifying Cl channels by protein kinase A corrected by insertion of CFTR. Nature 1992;358:581-4.
76. Nakamura H, Yoshimura K, McElvaney NG, et al. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic fibrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-84.
77. Bruce MC, Poncz L, Klinger JD, et al. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132:529-35.
78. Pick RB Jr, Nagel GP, Squier SU, et al. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. J Clin Invest 1984;74:236-48.
79. Berger M, Sorensen RU, Tosi MF, et al. Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J Clin Invest 1989;84:1302-13.
80. Tosi MF, Zakem H, Berger M. Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 in neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990;86:300-8.
81. Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria be- cause of abnormal airway surface fluid. Cell 1996;85:229-36.
82. Mearns M, Young W, Batten J. Transient pulmonary infiltrations in cystic fibrosis due to aspergillosis. Thorax 1995;20:385-92.
83. Hutchespn PS, Rejent AJ, Slavin RG. Variability in parameters of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. J Allergy Clin Immunol 1991;88:390-4.
84. Batten JC. Allergic aspergillosis: cystic fibrosis. Mod Probl Pediatr 1967;10:227-32.
85. Nelson LA, Callerame ML, Schwartz RH. Aspergillosis and atopy in cystic fibrosis. Am Rev Respir Dis 1979;120:863-73.
86. Brueton MJ, Ormerod LP, Shah KJ, et al. Allergic bronchopulmonary aspergillosis complicating cystic fibrosis in childhood. Arch Dis Child 1980;55:348-53.
87. Henry R, Mellis C, Simpson S, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. Aust Paediatr J 1982;18:110-3.
88. Laufer P, Fink J, Bruns W, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 1984;73:44-8.
89. Becker JW, Burke W, McDonald G, et al. Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis. Chest 1996;109:1536-40.
90. Greenberger P, Patterson R. Diagnosis and management of allergic bronchopulmonary aspergillosis. Ann Allergy 1986;56:444-8.
91. Neeld O, Goodman L, Gurney J, et al. Computer tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990;142:1200-5.
92. Nikolaizik WH, Moser M, Crameri R, et al. Identification of allergic bronchopulmonary aspergillosis in cystic fibrosis patients by recombinant Aspergillus fumigatus I/a-Specific Serology. Am J Respir Crit Care Med 1995;152:634-9.
93. Nikolaizik WH, Crameri R, Blaser K, et al. Skin test reactivity to recombinant Aspergillus fumigatus allergen I/a in patients with cystic fibrosis. Int Arch Allergy Immunol 1996;111:403-8.
94. Cystic Fibrosis Foundation. 1997. 1996 Annual Patient Data Registry, CF Foundation, Bethesda, MD.
95. Landau LI, Phelan PD. The variable effect of a bronchodilating agent on pulmonary function in cystic fibrosis. J Pediatr 1973;82:863-8.
96. Larsen GL, Barron RJ, Cotton EK, et al. A comparative study of inhaled atropine sulfate and iso-proterenol hydrochloride in cystic fibrosis. Am Rev Respir Dis 1979;119:399-407.
97. Kattan M, Mansell A, Levison H, et al. Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis. Thorax 1980;35:531-5.
98. Ormerol LP, Thomson RA, Anderson CM, et al. Reversible airway obstruction in cystic fibrosis. Thorax 1980;35:768-72.
99. Svenonius E, Arborelius MJ, Kautto R, et al. Lung function in cystic fibrosis. Respiration 1980;40:226-32.
100. Hordvik NL, Konig P, Morris D, et al. A longitudinal study of bronchodilator responsiveness in cystic fibrosis. Am Rev Respir Dis 1985;131:889-93.
101. Zach MS, Oberwaldner B, Forche G, et al. Bronchodilators increase airway instability in cystic fibrosis. Am Rev Respir Dis 1985;131:537-43.
102. Hiatt P, Eigen H, Yu P, et al. Bronchodilator responsiveness in infants and young children with cystic fibrosis. Am Rev Respir Dis 1988;137:119-22.
103. Pattishall EN. Longitudinal response of pulmonary function to bronchodilators in cystic fibrosis. Pediatr Pulmonol 1990;9:80-5.
104. König P, Gayer D, Barbero GJ, et al. Short-term and long-term effects of albuterol aerosol therapy in cysticfibrosis: a preliminary report. Pediatr Pulmonol 1995;20:205-14.
105. Sears MR, Taylor OR, Print CG, et al. Regular inhaled beta agonist treatment in bronchial asthma. Lancet 1990;336:1391-6.
106. Fuchs HJ, Borowitz DS, Chris- tiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-42.
107. Rock M, Kirchner K, McCubbin M, et al. Aerosol delivery and safety of rhDNase in young children with cystic fibrosis. A bronchoscopic study. Pediatr Pulmonol 1996;(Suppl)13:284A.
108. Knowles MR, Clarke LL, Boucher RC. Activation by extra-cellular nucleotides of chloride secretion in the airway epithelial of patients with cystic fibrosis. N Engl J Med 1991;325:533-8.
109. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;332:1189-94.
110. Graham AA, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243-8.
111. Wagner JA, Moran ML, Messner AH, et al. Safety of delivery of adeno-associated virus mediated gene transfer of CFTR in the maxillary sinus of CF patients with antrostomies. Pediatr Pulmonol 1996(Suppl)13:276A.
112. Welch WJ, Brown CR, Brown LQ, et al. Chemical chaperones correct the folding defect associated with the ΔF508 CFTR protein and restore cAMP dependent chloride transport. Pediatr Pulmonol 1996;(Suppl)13:90.
113. Yang I, Zeltwanger S, Wang F, et al. Pharmacological modulation of wild-type and ΔF508 CFTR by genistein and CPX. Pediatr Pulmonol 1996;(Suppl)13:258A.
114. Eidelman O, Guay-Broder C, vanGalen PJ, et al. A1 adenosine receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA, 1992;89:5562-6.
115. - mediated chloride permeability mediated chloride permeability is regulated by Type III phosphodiesterases in airway epithelial cells. Am J Respir Care Mol Biol 1995;13:657-64.
116. Browning J, Farley R, Smith S, et al. Effect of genistein on chloride secretions in CF tissues in vivo and in vitro. Pediatr Pulmonol 1996;(Suppl)13:281A.
117. Middleton PG, Chadwick SL, Pollard KA, et al. Milrinone induces chloride secretion in normal but not CF airways in vivo. Pediatric Pulmonol 1996;(Suppl)13:282A.
118. Mallory GB Jr. Lung transplantation for cystic fibrosis: state of the art. Pediatr Pulmonol 1996;(Suppl)13:121.
119. Cohen RG, Barr ML, Schenkel FA, et al. Living-related donor lobectomy for bilateral lobar transplantation in patients with cystic fibrosis. Ann Thorac Surg 1994;57:1473-8.